Research Signal – Source date 2026-01-13
Agitation, anxiety, sleep disruption and other behavioral changes can make Alzheimer’s disease distressing for the person experiencing them and difficult for caregivers. A review published January 13, 2026, examines whether the endocannabinoid system—the body’s own network of cannabis-like signaling molecules and receptors—might help explain these symptoms or offer a treatment target.
The review surveys animal research and varied human studies. Its most developed clinical discussion concerns agitation, including a randomized, placebo-controlled trial of nabilone. Reports involving other symptoms use different preparations and study designs. The findings are reasons for further study, not a settled treatment answer across the range of Alzheimer’s symptoms.
A signaling system with several routes to behavior
The endocannabinoid system includes two naturally produced signaling molecules, anandamide (AEA) and 2-arachidonoylglycerol (2-AG), the enzymes that make and break them down, and cannabinoid receptors known as CB1 and CB2. These molecules act as part of the body’s signaling system; they are not themselves cannabis products.
CB1 receptors are widespread in the brain, where they influence communication between nerve cells and the release of neurotransmitters. CB2 receptors are closely associated with immune activity and are found on microglia, immune-related cells in the brain. Their activity can affect inflammatory responses. Because Alzheimer’s disease involves changes in brain signaling and inflammation, both receptor pathways offer plausible ways the system could be connected to behavior.
Plausibility is not proof of symptom relief. The review describes reduced CB1 activity in some Alzheimer’s brain regions and discusses possible links to agitation, neurotransmitter balance and inflammation. Much of the mechanistic evidence comes from laboratory or animal studies. It cannot establish that the same pathway causes relief in people with Alzheimer’s disease.
Agitation has the clearest human treatment signal
The review describes several different human findings involving THC-related treatments, but they should not be read as one interchangeable result. In open-label studies, dronabinol, a synthetic form of THC, was associated with reduced agitation in people with Alzheimer’s disease. One report involving people with severe dementia described lower scores across agitation measures, as well as changes in sleep duration and meal consumption. An open-label study of medical cannabis oil containing THC also reported reduced neuropsychiatric symptom scores.
A different kind of evidence comes from a randomized, placebo-controlled trial of nabilone, a synthetic THC analog and partial CB1 agonist. The review reports reduced agitation, alongside improvements in overall neuropsychiatric symptoms, caregiver burden and nutritional status. Because participants were compared with a placebo group, this study provides a more controlled test than an open-label report, though one trial cannot settle how well the treatment works more broadly.
These studies involved distinct formulations, designs and outcomes. The open-label reports describe changes observed during treatment without a placebo comparison; the nabilone trial included one. Together they make agitation a notable area of human research, but they do not identify a dose or formulation that works across symptoms or stages of Alzheimer’s disease.
Sleep, appetite and anxiety bring different evidence
The review also describes findings for other symptoms, but the studies are smaller and more varied. For sleep-related problems, a two-week open-label study of dronabinol reported reduced nighttime movement and improved nighttime behavior ratings. A 16-week randomized trial of CBD-rich oil reported fewer behavioral disturbances than placebo, with improvement in sleep-related ratings. Observational reports of THC:CBD oil also described changes in sleep-disturbance scores. These are different products, designs and measures, so they do not establish a common sleep effect.
Appetite was examined in a small double-blind, placebo-controlled crossover trial: 15 people with Alzheimer’s were enrolled, and 12 were included in the analysis. During dronabinol treatment, participants gained more weight and had improved triceps skinfold measurements; agitation scores also fell. This result concerns a particular small study and does not by itself show that appetite or agitation will improve for other patients.
For anxiety, an open-label observational cohort used a CBD-dominant formulation with a high CBD-to-THC ratio. The review reports reductions in anxiety, agitation and aggression, as well as caregiver burden. Without a placebo comparison, changes cannot be attributed with confidence to the formulation. The cohort also cannot show that the same outcome would follow from other cannabinoid products.
Dose changes the safety question
The system’s influence on brain signaling helps explain why cannabinoid treatment has a tradeoff. CB1 activity can affect processes involved in behavior, but strong or prolonged activation may also interfere with normal signaling. The review discusses evidence that high cannabinoid doses can impair memory and that chronic CB1 activation can desensitize the receptor, reducing its responsiveness.
This matters especially in a disease that affects cognition. A behavioral change that appears helpful would need to be weighed against cognitive effects and other adverse effects over time. The studies reviewed do not establish durable cognitive safety, and they do not show that easing behavioral symptoms slows Alzheimer’s pathology.
The review also discusses FAAH and MAGL inhibitors, which would alter how the body breaks down its own endocannabinoids rather than directly supplying a cannabinoid agonist. These compounds are a research direction, with preclinical findings and an ongoing investigation noted by the review. They are not established as a safer or effective treatment for Alzheimer’s symptoms.
Why the findings remain difficult to compare
Across the human studies, sample sizes were often small or not adequate to reliably test predefined outcomes. Researchers used different behavioral rating scales, studied people at different stages of Alzheimer’s disease, and examined symptoms that may have distinct underlying mechanisms. The interventions also ranged from synthetic THC-related medicines to cannabis oils with differing cannabinoid compositions.
Those differences limit how far any one result can travel. A change on an agitation scale in one study does not answer whether a different preparation will improve anxiety or sleep, or whether benefits and risks will hold over longer treatment. The review presents a promising area of investigation, while calling for more placebo-controlled randomized trials to clarify efficacy and safety.
What safer symptom relief could mean for Alzheimer’s families
For families, a validated option that eased a specific disruptive symptom without worsening cognition could reduce distress for the person with Alzheimer’s and lessen some caregiver burden. That practical benefit depends on reproducible clinical improvement and acceptable safety in the people who would use it. The research reviewed here has not yet established that balance, and symptom relief would not itself mean the disease had slowed.
Key Sources
- Primary source: The role of the endocannabinoid system in managing neuropsychiatric symptoms in Alzheimer's disease.
DOI or Journal Page · Review or Meta-Analysis · 2026-01-13
Keep exploring